Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Search

Page Path
HOME > Search
3 "Young Mi Lee"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Article
Serum Cystatin C Reflects the Progress of Albuminuria
Jeong Seon Yoo, Young Mi Lee, Eun Hae Lee, Ji Woon Kim, Shin Young Lee, Ki-Cheon Jeong, Shin Ae Kang, Jong Suk Park, Joo Young Nam, Chul Woo Ahn, Young Duk Song, Kyung Rae Kim
Diabetes Metab J. 2011;35(6):602-609.   Published online December 26, 2011
DOI: https://doi.org/10.4093/dmj.2011.35.6.602
  • 4,480 View
  • 38 Download
  • 5 Crossref
AbstractAbstract PDFPubReader   
Background

Research on the relationship between urinary albumin excretion and serum cystatin C in diabetes is restricted to cross-sectional studies. In this study, we investigated how well serial measurements of serum cystatin C level reflect changes in the urinary albumin excretion rate.

Methods

We enrolled and retrospectively collected data on 1,058 participants with type 2 diabetes who were older than 18 years and who had more than 3 years of follow-up with serial measurements of albuminuria and serum cystatin C at an outpatient clinic.

Results

With the use of a linear mixed model, we found that the albuminuria level for each patient over time corresponded with the annual change in serum cystatin C-based estimated glomerular filtration rate (cysC-eGFR) but did not correspond with the creatinine-based eGFR calculated by the modification of diet in renal disease formula (MDRD-eGFR). The discrepancy in the direction of the trend was smaller with cysC-eGFR than with MDRD-eGFR.

Conclusion

Serum cystatin C level reflects the trend in albuminuria level more accurately than serum creatinine level in Korean type 2 diabetes mellitus patients.

Citations

Citations to this article as recorded by  
  • Assessment of Cystatin C and Microalbumin as Biomarkers for Nephropathy in Patients with Type 2 Diabetes Mellitus
    Bhuneshwar Yadav, Shashidhar K.N, Raveesha A, Muninarayana C.
    Journal of Evolution of Medical and Dental Sciences.2021; 10(25): 1866.     CrossRef
  • Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
    Eugene Han, Mi Kyung Kim, Byoung Kuk Jang, Hye Soon Kim
    Diabetes & Metabolism Journal.2021; 45(5): 698.     CrossRef
  • Increase of BACE1, Brain-Renal Risk Factor, Contributes to Kidney Damage in an Alzheimer’s Disease Mouse Model
    Yan Shi, Feng Gao, Xiaoli Yang, Dongwei Liu, Qiuxia Han, Zhangsuo Liu, Hanyu Zhu, Yong Shen
    Journal of Alzheimer's Disease.2020; 76(1): 237.     CrossRef
  • Lower Leg Fat Depots Are Associated with Albuminuria Independently of Obesity, Insulin Resistance, and Metabolic Syndrome (Korea National Health and Nutrition Examination Surveys 2008 to 2011)
    Eugene Han, Nan Hee Cho, Mi Kyung Kim, Hye Soon Kim
    Diabetes & Metabolism Journal.2019; 43(4): 461.     CrossRef
  • Evaluation of creatinine-based and cystatin C-based equations for estimation of glomerular filtration rate in type 1 diabetic patients
    Caroline Pereira Domingueti, Rodrigo Bastos Fóscolo, Ana Cristina Simões e Silva, Luci Maria S. Dusse, Janice Sepúlveda Reis, Maria das Graças Carvalho, Ana Paula Fernandes, Karina Braga Gomes
    Archives of Endocrinology and Metabolism.2016; 60(2): 108.     CrossRef
Response
Response: Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus (Diabetes Metab J 2011;35:159-65)
Soon Ae Kim, Woo Ho Shim, Eun Hae Lee, Young Mi Lee, Sun Hee Beom, Eun Sook Kim, Jeong Seon Yoo, Ji Sun Nam, Min Ho Cho, Jong Suk Park, Chul Woo Ahn, Kyung Rae Kim
Diabetes Metab J. 2011;35(3):300-301.   Published online June 30, 2011
DOI: https://doi.org/10.4093/dmj.2011.35.3.300
  • 3,373 View
  • 27 Download
  • 1 Crossref
PDFPubReader   

Citations

Citations to this article as recorded by  
  • Efficacy and Safety of Switching from Sitagliptin to Ipragliflozin in Obese Japanese Patients with Type 2 Diabetes Mellitus: A Single-Arm Multicenter Interventional Study
    Kentaro Watanabe, Susumu Yamaguchi, Yoshinori Kosakai, Tetsuya Ioji, Hisamitsu Ishihara
    Clinical Drug Investigation.2023; 43(12): 927.     CrossRef
Original Article
Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus
Soon Ae Kim, Woo Ho Shim, Eun Hae Lee, Young Mi Lee, Sun Hee Beom, Eun Sook Kim, Jeong Seon Yoo, Ji Sun Nam, Min Ho Cho, Jong Suk Park, Chul Woo Ahn, Kyung Rae Kim
Diabetes Metab J. 2011;35(2):159-165.   Published online April 30, 2011
DOI: https://doi.org/10.4093/dmj.2011.35.2.159
  • 4,490 View
  • 53 Download
  • 40 Crossref
AbstractAbstract PDFPubReader   
Background

Sitagliptin is a highly selective dipeptidyl peptide-4 (DPP-4) inhibitor that increases blood levels of active glucagon-like peptide (GLP)-1 and glucose-dependent insulinotrophic polypeptide (GIP), resulting in increased insulin secretion. While studies conducted in other countries have indicated the efficacy and safety of using sitagliptin to treat type 2 diabetes mellitus (T2DM), its predictors of effects to sitagliptin are not well understood. Therefore, we evaluated the predictive clinical parameters for the therapeutic benefits of sitagliptin when added to an ongoing metformin or sulfonylurea therapy in Korean T2DM subjects.

Methods

We obtained data from 251 Korean T2DM subjects who had recently started taking sitagliptin as add-on therapy. Exclusion criteria included any insulin use. Changes in HbA1c (ΔHbA1c) and fasting plasma glucose (ΔFPG) were assessed by comparing baseline levels prior to sitagliptin administration to levels 12 and 24 weeks after treatment. Responders were defined as subjects who experienced decrease from baseline of >10% in ΔHbA1c or >20% in ΔFPG levels at 24 weeks.

Results

We classified 81% of the subjects (204 out of 251) as responders. The responder group had a lower mean body mass index (23.70±2.40 vs. 26.00±2.26, P≤0.01) and were younger (58.83±11.57 years vs. 62.87±12.09 years, P=0.03) than the non-responder group.

Conclusion

In Korean T2DM subjects, sitagliptin responders had lower body mass index and were younger compared to non-responders.

Citations

Citations to this article as recorded by  
  • Predictors of Responsiveness to GLP-1 Receptor Agonists in Insulin-Treated Patients with Type 2 Diabetes
    Colleen Gavigan, Thomas Donner, Christian S. Goebl
    Journal of Diabetes Research.2023; 2023: 1.     CrossRef
  • Comparative Effects of Metformin and Dipeptidyl Peptidase-4 Inhibitors in Japanese Obese Patients with Type 2 Diabetes: A Claims Database Study
    Masato Odawara, Sumiko Aoi, Tomomi Takeshima, Kosuke Iwasaki
    Diabetes Therapy.2021; 12(8): 2165.     CrossRef
  • Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials
    A.J. Scheen
    Diabetes & Metabolism.2020; 46(3): 186.     CrossRef
  • Factors associated with the glucose‐lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials
    Naoko Tajima, Jun‐ichi Eiki, Taro Okamoto, Kotoba Okuyama, Masaru Kawashima, Samuel S Engel
    Journal of Diabetes Investigation.2020; 11(3): 640.     CrossRef
  • Development of a 13C Stable Isotope Assay for Dipeptidyl Peptidase-4 Enzyme Activity A New Breath Test for Dipeptidyl Peptidase Activity
    Roger Yazbeck, Simone Jaenisch, Michelle Squire, Catherine A. Abbott, Emma Parkinson-Lawrence, Douglas A. Brooks, Ross N. Butler
    Scientific Reports.2019;[Epub]     CrossRef
  • Pharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetes
    Wen-Ling Liao, Wen-Jane Lee, Ching-Chu Chen, Chieh Hsiang Lu, Chien-Hsiun Chen, Yi-Chun Chou, I-Te Lee, Wayne H-H Sheu, Jer-Yuarn Wu, Chi-Fan Yang, Chung-Hsing Wang, Fuu-Jen Tsai
    Oncotarget.2017; 8(11): 18050.     CrossRef
  • Efficacy and safety of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24‐week, randomized, double‐blind, placebo‐controlled trial
    Takashi Kadowaki, Nobuya Inagaki, Kazuoki Kondo, Kenichi Nishimura, Genki Kaneko, Nobuko Maruyama, Nobuhiro Nakanishi, Hiroaki Iijima, Yumi Watanabe, Maki Gouda
    Diabetes, Obesity and Metabolism.2017; 19(6): 874.     CrossRef
  • A Practical Review of C-Peptide Testing in Diabetes
    Emma Leighton, Christopher AR Sainsbury, Gregory C. Jones
    Diabetes Therapy.2017; 8(3): 475.     CrossRef
  • Efficacy and safety of linagliptin according to patient baseline characteristics: A pooled analysis of three phase 3 trials
    S. Del Prato, S. Patel, S. Crowe, M. von Eynatten
    Nutrition, Metabolism and Cardiovascular Diseases.2016; 26(10): 886.     CrossRef
  • Soluble DPP-4 up-regulates toll-like receptors and augments inflammatory reactions, which are ameliorated by vildagliptin or mannose-6-phosphate
    Dong-Sung Lee, Eun-Sol Lee, Md. Morshedul Alam, Jun-Hyeog Jang, Ho-Sub Lee, Hyuncheol Oh, Youn-Chul Kim, Zahid Manzoor, Young-Sang Koh, Dae-Gil Kang, Dae Ho Lee
    Metabolism.2016; 65(2): 89.     CrossRef
  • Efficacy of hypoglycemic treatment in type 2 diabetes stratified by age or diagnosed age: a meta-analysis
    Xiaoling Cai, Wenjia Yang, Yifei Chen, Xueying Gao, Lingli Zhou, Simin Zhang, Xueyao Han, Linong Ji
    Expert Opinion on Pharmacotherapy.2016; 17(12): 1591.     CrossRef
  • Baseline Body Mass Index and the Efficacy of Hypoglycemic Treatment in Type 2 Diabetes: A Meta-Analysis
    Xiaoling Cai, Wenjia Yang, Xueying Gao, Lingli Zhou, Xueyao Han, Linong Ji, Francesco Giorgino
    PLOS ONE.2016; 11(12): e0166625.     CrossRef
  • Predictive Factors for the Therapeutic Response to Concomitant Treatment with DPP-4 Inhibitors in Type 2 Diabetes with Short-Term Follow-Up
    Jong-Ha Baek, Bo Ra Kim, Jeong Woo Hong, Soo Kyoung Kim, Jung Hwa Jung, Jaehoon Jung, Jong Ryeal Hahm
    Kosin Medical Journal.2016; 31(2): 146.     CrossRef
  • Complementary glucagonostatic and insulinotropic effects of DPP-4 inhibitors in the glucose-lowering action in Japanese patients with type 2 diabetes
    Ken-ichi Hashimoto, Yukio Horikawa, Jun Takeda
    Diabetology International.2016; 7(2): 133.     CrossRef
  • Anagliptin and sitagliptin as add‐ons to metformin for patients with type 2 diabetes: a 24‐week, multicentre, randomized, double‐blind, active‐controlled, phase III clinical trial with a 28‐week extension
    S.‐M. Jin, S. W. Park, K.‐H. Yoon, K. W. Min, K.‐H. Song, K. S. Park, J.‐Y. Park, I. B. Park, C. H. Chung, S. H. Baik, S. H. Choi, H. W. Lee, I.‐K. Lee, D.‐M. Kim, M.‐K. Lee
    Diabetes, Obesity and Metabolism.2015; 17(5): 511.     CrossRef
  • Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus
    Hyun Min Kim, Jung Soo Lim, Byung-Wan Lee, Eun-Seok Kang, Hyun Chul Lee, Bong-Soo Cha
    Endocrinology and Metabolism.2015; 30(1): 84.     CrossRef
  • C-peptide immunoreactivity index is associated with improvement of HbA1c: 2-Year follow-up of sitagliptin use in patients with type 2 diabetes
    Takeshi Nishimura, Shu Meguro, Risa Sekioka, Karin Tanaka, Yoshifumi Saisho, Junichiro Irie, Masami Tanaka, Toshihide Kawai, Hiroshi Itoh
    Diabetes Research and Clinical Practice.2015; 108(3): 441.     CrossRef
  • Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin
    Ye An Kim, Won Sang Yoo, Eun Shil Hong, Eu Jeong Ku, Kyeong Seon Park, Soo Lim, Young Min Cho, Kyong Soo Park, Hak Chul Jang, Sung Hee Choi
    Diabetes & Metabolism Journal.2015; 39(6): 489.     CrossRef
  • Response to the dipeptidyl peptidase‐4 inhibitors in Japanese patients with type 2 diabetes might be associated with a diplotype of two single nucleotide polymorphisms on the interleukin‐6 promoter region under a certain level of physical activity
    Mizue Matsui, Yoshihiko Takahashi, Noriko Takebe, Kazuma Takahashi, Kan Nagasawa, Hiroyuki Honma, Tomoyasu Oda, Mitsutaka Ono, Riyuki Nakagawa, Takayoshi Sasai, Hirobumi Togashi, Mari Hangai, Takashi Kajiwara, Haruhito Taneichi, Yasushi Ishigaki, Jo Satoh
    Journal of Diabetes Investigation.2015; 6(2): 173.     CrossRef
  • Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes Mellitus
    Ji Hyun Kim
    Diabetes & Metabolism Journal.2015; 39(4): 304.     CrossRef
  • Effects of 6-Month Sitagliptin Treatment on Insulin and Glucagon Responses in Korean Patients with Type 2 Diabetes Mellitus
    Hae Kyung Yang, Borami Kang, Seung-Hwan Lee, Hun-Sung Kim, Kun-Ho Yoon, Bong-Yun Cha, Jae-Hyoung Cho
    Diabetes & Metabolism Journal.2015; 39(4): 335.     CrossRef
  • GLP-1: The Oracle for Gastric Bypass?
    Gema Frühbeck, Ruben Nogueiras
    Diabetes.2014; 63(2): 399.     CrossRef
  • Effects of concomitant drugs on sitagliptin-mediated improvement in glycemic control in Japanese patients with type 2 diabetes
    Takumi Hirata, Kouichi Inukai, Jiro Morimoto, Shigehiro Katayama, Hitoshi Ishida
    Primary Care Diabetes.2014; 8(3): 265.     CrossRef
  • Predictive clinical parameters for the hemoglobin A1c-lowering effect of vildagliptin in Japanese patients with type 2 diabetes
    Yukihiro Bando, Masayuki Yamada, Keiko Aoki, Hideo Kanehara, Azusa Hisada, Kazuhiro Okafuji, Daisyu Toya, Nobuyoshi Tanaka
    Diabetology International.2014; 5(4): 229.     CrossRef
  • The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes
    Eun Yeong Choe, Yongin Cho, Younjeong Choi, Yujung Yun, Hye Jin Wang, Obin Kwon, Byung-Wan Lee, Chul Woo Ahn, Bong Soo Cha, Hyun Chul Lee, Eun Seok Kang
    Diabetes & Metabolism Journal.2014; 38(3): 211.     CrossRef
  • Very Short-Term Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on the Secretion of Insulin, Glucagon, and Incretin Hormones in Japanese Patients with Type 2 Diabetes Mellitus: Analysis of Meal Tolerance Test Data
    Kazuki Murai, Tomoyuki Katsuno, Jun-ichiro Miyagawa, Toshihiro Matsuo, Fumihiro Ochi, Masaru Tokuda, Yoshiki Kusunoki, Masayuki Miuchi, Mitsuyoshi Namba
    Drugs in R&D.2014; 14(4): 301.     CrossRef
  • Variation at the DPP4 locus influences apolipoprotein B levels in South Asians and exhibits heterogeneity in Europeans related to BMI
    Swneke D. Bailey, Changchun Xie, Guillaume Paré, Alexandre Montpetit, Viswanathan Mohan, Salim Yusuf, Hertzel Gerstein, James C. Engert, Sonia S. Anand
    Diabetologia.2014; 57(4): 738.     CrossRef
  • Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride
    Rieko Umayahara, Takako Yonemoto, Chika Kyou, Kae Morishita, Tatsuo Ogawa, Yoshitaka Taguchi, Tatsuhide Inoue
    Endocrine Journal.2014; 61(12): 1163.     CrossRef
  • The clinical utility of C‐peptide measurement in the care of patients with diabetes
    A. G. Jones, A. T. Hattersley
    Diabetic Medicine.2013; 30(7): 803.     CrossRef
  • Predictive clinical characteristics for the efficacy of vildagliptin monotherapy in Japanese patients with type 2 diabetes mellitus: a multicenter study
    Naotsuka Okayama, Kenro Imaeda, Takashi Kato, Soji Iwase, Hideomi Ohguchi, Takashi Joh, Yoshinari Hayashi, Masaya Akao, Kohei Ogawa, Mayo Hachiya, Rei Hattori, Ryosuke Kimura, Sachie Yasui, Misao Ando, Yasunari Jinno, Nobuo Takahashi, Manabu Shimizu, Nobo
    Diabetology International.2013; 4(3): 179.     CrossRef
  • Clinical Characteristics of the Responders to Dipeptidyl Peptidase-4 Inhibitors in Korean Subjects with Type 2 Diabetes
    Tae Jung Oh, Hye Seung Jung, Jae Hyun Bae, Yeong Gi Kim, Kyeong Seon Park, Young Min Cho, Kyong Soo Park, Seong Yeon Kim
    Journal of Korean Medical Science.2013; 28(6): 881.     CrossRef
  • Determinants of the HbA1c-lowering effect of sitagliptin when added to ongoing insulin therapy in Japanese patients with type 2 diabetes
    Yukihiro Bando, Kazuhide Ishikura, Hideo Kanehara, Keiko Aoki, Azusa Hisada, Daisyu Toya, Nobuyoshi Tanaka
    Diabetology International.2013; 4(4): 251.     CrossRef
  • The Efficacy of Vildagliptin in Korean Patients with Type 2 Diabetes
    Jun Sung Moon, Kyu Chang Won
    Diabetes & Metabolism Journal.2013; 37(1): 36.     CrossRef
  • Factors Influencing Glycemic Control Response of Sitagliptin
    Gun Woo Kim, Jae Hyun Kim, Mi Young Lee, Jang Yel Shin, Young Goo Shin, Eun Ho Ha, Choon Hee Chung
    The Journal of Korean Diabetes.2013; 14(4): 206.     CrossRef
  • Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes
    S-I. Harashima, M. Ogura, D. Tanaka, T. Fukushima, Y. Wang, T. Koizumi, M. Aono, Y. Murata, M. Seike, N. Inagaki
    International Journal of Clinical Practice.2012; 66(5): 465.     CrossRef
  • Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study
    Soo Lim, Jee Hyun An, Hayley Shin, Ah Reum Khang, Yenna Lee, Hwa Young Ahn, Ji Won Yoon, Seon Mee Kang, Sung Hee Choi, Young Min Cho, Kyong Soo Park, Hak Chul Jang
    Clinical Endocrinology.2012; 77(2): 215.     CrossRef
  • Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan
    Yuji Tajiri, Munehisa Tsuruta, Tsuyoshi Ohki, Tomoko Kato, Yuko Sasaki, Kayo Tanaka, Shusuke Kono, Masayuki Tojikubo, Kentaro Yamada
    Endocrine Journal.2012; 59(3): 197.     CrossRef
  • Comparison between sitagliptin as add‐on therapy to insulin and insulin dose‐increase therapy in uncontrolled Korean type 2 diabetes: CSI study
    E. S. Hong, A. R. Khang, J. W. Yoon, S. M. Kang, S. H. Choi, K. S. Park, H. C. Jang, H. Shin, G. A. Walford, S. Lim
    Diabetes, Obesity and Metabolism.2012; 14(9): 795.     CrossRef
  • Letter: Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus (Diabetes Metab J 2011;35:159-65)
    Jee-Young Oh
    Diabetes & Metabolism Journal.2011; 35(3): 298.     CrossRef
  • Candidate Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes
    Yun-Mi Jang, Dong-Lim Kim
    Diabetes & Metabolism Journal.2011; 35(2): 117.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal